Canada authorises compulsory licences for COVID-19 shortfalls
27-03-2020
Pharma industry challenges Canada’s drug pricing plan
09-09-2019
Fabio Berti / Shutterstock.com
The final version of guidelines issued by Canada’s federal drug price regulator last week has caused uproar among the pharma industry.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Innovative Medicines Canada, drug pricing, Canadian government, generics, Patented Medicine Prices Review Board, Life Sciences Ontario
